Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities. The deal also includes additional ...

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

A UK company developing technology spun out of the University of Queensland is poised for growth after being acquired by ...

Sanofi’s $1.76 billion acquisition of Vicebio has delivers a windfall for the University of Queensland — and highlighted a ...

It’s not a love-in yet and Hutchies boss Scott Hutchinson still reckons unions are “a pain in the ass” but relations are improving with just seven years to go before the opening ceremony of the 2032 ...

Sanofi acquires UQ-linked biotech Vicebio for up to US$1.6b, marking Australia’s largest university commercialisation deal.

Health care companies recouped some of their recent losses amid generally strong earnings and deal activity. British drug maker AstraZeneca said it plans to invest $50 billion in the U.S. by 2030, ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion ...

George Tidmarsh, a Stanford University physician who founded Horizon Pharma and later ran La Jolla Pharma, was named head of ...

Astra, led by boss Pascal Soriot (pictured), said it is accelerating its expansion in US with an investment that will create ...

“Vicebio’s Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine ...

Sanofi is acquiring UK biotechnology company Vicebio for up to US$1.6 billion ($2.4 billion) in the largest deal involving a ...